Menu
← Oncology Approval Tracker
FDA DECISION ·
Cyramza + erlotinib
ramucirumab + erlotinib · Eli Lilly
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
First-line treatment for metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R substitution.
LAMPGEN ANALYSIS
Why it matters
Added VEGFR2 inhibition to an EGFR-directed regimen for two common sensitizing alterations.
What research teams should watch
Match the exact EGFR variant and plan blood pressure and proteinuria monitoring.
PRIMARY RECORDS